AbCellera Biologics Inc.
ABCL | NASDAQ
$12.66
+$0.03 (+0.24%)
At close: Sep 21, 2026, 4:00 PM ET
$12.61
-$0.05 (-0.39%)
Pre-market:
Sep 22, 2026, 6:17 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 75.13M | 28.83M | 38.03M | 485.42M | 375.2M | 233.16M |
Cost of Revenue | 28.82M | n/a | n/a | 66.44M | 45.52M | 27.14M |
Gross Profit | 46.31M | 28.83M | 38.03M | 418.99M | 329.69M | 206.01M |
Operating Income | -217.1M | -314.77M | -237.21M | 216.51M | 204.41M | 156.03M |
Interest Income | 28.33M | 38.47M | 42.25M | 16.08M | 3.33M | 293K |
Pretax Income | -177.6M | -200.4M | -174.03M | 239.1M | 219.15M | 157.83M |
Net Income | -146.41M | -162.86M | -146.4M | 158.52M | 153.46M | 118.92M |
Selling & General & Admin | 76.58M | 85.49M | 75.18M | 66.76M | 48.76M | 15.75M |
Research & Development | 186.83M | 167.26M | 175.66M | 107.88M | 62.06M | 29.39M |
Other Expenses | n/a | 90.85M | 24.4M | 27.84M | 14.45M | 4.84M |
Operating Expenses | 263.41M | 343.6M | 275.23M | 202.48M | 125.27M | 49.98M |
Interest Expense | n/a | n/a | n/a | 4.05M | 5.23M | 6.51M |
Selling & Marketing Expenses | n/a | 12.78M | 14.18M | 11.27M | 6.91M | 3.84M |
Cost & Expenses | 292.23M | 343.6M | 275.23M | 268.91M | 170.79M | 77.12M |
Income Tax Expense | -31.18M | -37.54M | -27.63M | 80.58M | 65.69M | 38.92M |
Shares Outstanding (Basic) | 298.71M | 294.33M | 289.17M | 285.06M | 275.76M | 263.13M |
Shares Outstanding (Diluted) | 298.71M | 294.33M | 289.17M | 314.83M | 318.29M | 263.13M |
EPS (Basic) | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 | 0.45 |
EPS (Diluted) | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 | 0.45 |
EBITDA | -148.77M | -204.15M | -192.16M | 260.17M | 239.15M | 169.62M |
EBIT | -177.6M | -301.15M | -223.05M | 227.07M | 221.9M | 164.34M |
Depreciation & Amortization | 28.82M | 97M | 30.89M | 33.1M | 17.25M | 5.27M |
Add to Watchlist
Select watchlists to add or remove ABCL